Home › Compare › ATBPF vs O

ATBPF vs O: Dividend Comparison 2026

ATBPF yields 927.64% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATBPF wins by $9822464.73M in total portfolio value
10 years
ATBPF
ATBPF
● Live price
927.64%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9822464.76M
Annual income
$8,103,949,924,179.18
Full ATBPF calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — ATBPF vs O

📍 ATBPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATBPFO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATBPF + O cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ATBPF pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATBPF
Annual income on $10K today (after 15% tax)
$78,849.72/yr
After 10yr DRIP, annual income (after tax)
$6,888,357,435,552.30/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, ATBPF beats the other by $6,888,357,431,214.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATBPF + O for your $10,000?

ATBPF: 50%O: 50%
100% O50/50100% ATBPF
Portfolio after 10yr
$4911232.40M
Annual income
$4,051,974,964,640.96/yr
Blended yield
82.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

ATBPF
No analyst data
Altman Z
-3.8
Piotroski
1/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATBPF buys
0
O buys
0
No recent congressional trades found for ATBPF or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATBPFO
Forward yield927.64% ✓5.28%
Annual dividend / share$2.00$3.23 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1% ✓
Portfolio after 10y$9822464.76M ✓$34.2K
Annual income after 10y$8,103,949,924,179.18 ✓$5,102.74
Total dividends collected$9689719.06M ✓$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: ATBPF vs O ($10,000, DRIP)

YearATBPF PortfolioATBPF Income/yrO PortfolioO Income/yrGap
1← crossover$103,464$92,764.38$10,818$608.16+$92.6K → ATBPF
2$1,007,698$896,991.47$11,787$741.68+$995.9K → ATBPF
3$9,243,012$8,164,775.26$12,946$911.00+$9.23M → ATBPF
4$79,881,224$69,991,201.10$14,345$1,127.94+$79.87M → ATBPF
5$650,788,343$565,315,433.07$16,056$1,409.05+$650.77M → ATBPF
6$5,000,639,395$4,304,295,867.45$18,171$1,777.83+$5000.62M → ATBPF
7$36,261,047,555$30,910,363,402.53$20,820$2,268.21+$36261.03M → ATBPF
8$248,275,740,228$209,476,419,343.92$24,188$2,929.90+$248275.72M → ATBPF
9$1,606,088,634,392$1,340,433,592,348.06$28,533$3,837.11+$1606088.61M → ATBPF
10$9,822,464,762,978$8,103,949,924,179.18$34,235$5,102.74+$9822464.73M → ATBPF

ATBPF vs O: Complete Analysis 2026

ATBPF — Stock

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.

Full ATBPF Calculator →

O — REIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this ATBPF vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATBPF vs SCHDATBPF vs JEPIATBPF vs KOATBPF vs MAINATBPF vs STAGATBPF vs ADCATBPF vs NNNATBPF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.